Innovative Enhanced Medication Therapy Management Model: MedWise Risk Score, Medication Safety Review, and Health Care Outcomes - Participating Faculty

Faculty

Michael S. Awadalla, PharmD, BCGP
Executive Vice President
Office of Applied Pharmacotherapy
Tabula Rasa HealthCare
Moorestown, NJ

David Bankes, PharmD, BCGP
Research Pharmacist
Office of Translational Research and Residency Programs
Tabula Rasa HealthCare
Moorestown, NJ

Ravil Bikmetov, PhD
Research Data Scientist
Precision Pharmacotherapy Research and Development Institute
Tabula Rasa HealthCare
Orlando, FL

Pamela Dow, MS
Clinical Research Manager
Precision Pharmacotherapy Research and Development Institute
Tabula Rasa HealthCare
Orlando, FL

Stephanie Finnel, PhD
Director
Office of Healthcare Analytics
Tabula Rasa HealthCare
Moorestown, NJ

Huaichuan Jin, MS
Senior Data Scientist
Office of Healthcare Analytics
Tabula Rasa HealthCare
Moorestown, NJ

Joshua Johnson, PharmD, BCGP
Program Administrator
Enhanced MTM
ClearStone Solutions
Government Markets Division
Blue Cross and Blue Shield of Minnesota
Eagan, MN

Veronique Michaud, BPharm, PhD
Chief Operating Officer
Precision Pharmacotherapy Research and Development Institute
Tabula Rasa HealthCare
Orlando, FL
Adjunct Professor
Faculty of Pharmacy
Université de Montréal
Montréal, Quebec, Canada

Katie Pizzolato, PharmD
PGY2 Pharmacy Resident in Clinical Pharmacogenomics
Office of Translational Research and Residency Programs
Tabula Rasa HealthCare
Moorestown, NJ

Matt K. Smith, PhD
Research Data Scientist
Precision Pharmacotherapy Research and Development Institute
Tabula Rasa HealthCare
Orlando, FL

Alan Stein, MD, PhD
Senior Vice President
Office of Healthcare Analytics
Tabula Rasa HealthCare
Moorestown, NJ

Jacques Turgeon, BPharm, PhD
Chief Scientific Officer
Tabula Rasa HealthCare
Orlando, FL
Emeritus Professor
Université de Montréal
Montréal, Quebec, Canada

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:

Michael S. Awadalla, PharmD, BCGP
EMPLOYMENT
Tabula Rasa HealthCare
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score and provided the services used in this study.

David Bankes, PharmD, BCGP
EMPLOYMENT
Tabula Rasa HealthCare
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score and provided the services used in this study.

Ravil Bikmetov, PhD
EMPLOYMENT
Tabula Rasa HealthCare
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score used in this study.

Pamela Dow, MS
EMPLOYMENT
Tabula Rasa HealthCare
GRANTS
Coinvestigator on National Institutes of Health grant approved using the MedWise Risk Score
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score used in this study.

Stephanie Finnel, PhD
EMPLOYMENT
Tabula Rasa HealthCare
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score used in this study.

Huaichuan Jin, MS
EMPLOYMENT
Tabula Rasa HealthCare
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score and provided the services used in this study.

Joshua Johnson, PharmD, BCGP
EMPLOYMENT
ClearStone Solutions, affiliate of Blue Cross and Blue Shield of Minnesota
INSTITUTIONAL CONFLICTS OF INTEREST
ClearStone Solutions administers the Enhanced Medication Therapy Management pilot on behalf of Blue Cross and Blue Shield Northern Plains Alliance. ClearStone Solutions paid Tabula Rasa HealthCare to provide the Enhanced Medication Therapy Management services described in this supplement.

Veronique Michaud, BPharm, PhD
EMPLOYMENT
Tabula Rasa HealthCare
GRANTS
Coinvestigator on National Institutes of Health grant approved using the MedWise Risk Score
PATENTS PENDING
Methods of treatment having reduced drug-related toxicity and methods of identifying
the likelihood of patient harm arising from prescribed medications: 17/143,936
Population-based medication risk stratification and personalized medication risk score: 16/870,517
PATENTS RECEIVED
10,890,577: Methods of treatment having reduced drug-related toxicity and methods
of identifying the likelihood of patient harm arising from prescribed medications
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score used in this study.

Katie Pizzolato, PharmD
EMPLOYMENT
Tabula Rasa HealthCare
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the clinical decision support system and MedWise Risk Score described and was responsible for the delivery of Enhanced Medication Therapy Management services as part of this study.

Matt K. Smith, PhD
EMPLOYMENT
Tabula Rasa HealthCare
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score used in this study.

Alan Stein, MD, PhD
EMPLOYMENT
Tabula Rasa HealthCare
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score used in this study.

Jacques Turgeon, BPharm, PhD
EMPLOYMENT
Tabula Rasa HealthCare
GRANTS
Coinvestigator on National Institutes of Health grant approved using the MedWise Risk Score
PATENTS PENDING
Methods of treatment having reduced drug-related toxicity and methods of identifying
the likelihood of patient harm arising from prescribed medications: 17/143,936
Population-based medication risk stratification and personalized medication risk score: 16/870,517
PATENTS RECEIVED
10,890,577: Methods of treatment having reduced drug-related toxicity and methods
of identifying the likelihood of patient harm arising from prescribed medications
STOCK OWNERSHIP
Tabula Rasa HealthCare
INSTITUTIONAL CONFLICTS OF INTEREST
Tabula Rasa HealthCare owns the MedWise Risk Score used in this study.

Download PDF